

## Antibody Raised against Soluble CD4-rgp120 Complex Recognizes the CD4 Moiety and Blocks Membrane Fusion without Inhibiting CD4-gp120 Binding

By Franco Celada,\* Caterina Cambiaggi,\* Joan Maccari,\* Samuele Burastero,† Timothy Gregory,§ Eric Patzer,§ James Porter,§ Charlene McDanal,|| and Thomas Matthews||

From the \*Institute for Molecular Immunology, Hospital for Joint Diseases, and Department of Pathology, New York University, New York, New York 10003; the †Department of Immunology, University of Genoa, Genoa 16132 Italy; the §Departments of Recovery Process, R & D, and Medicinal and Analytical Chemistry, Genentech Inc., South San Francisco, California 94080; and the ||Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710

### Summary

We studied the humoral response of mice immunized with soluble CD4-rgp120 complex, testing polyclonal and monoclonal antibodies (mAbs) with the aim of identifying molecular changes that take place after the first interaction between human immunodeficiency virus and the cell surface. The antisera had a paradoxically high syncytia-blocking titer associated with anti-CD4 specificity, while their capacity to inhibit CD4-gp120 binding was relatively modest. One of the mAbs produced from these responders blocks syncytia formation but does not inhibit CD4 interaction with gp120. Apparently, this mAb interacts with the CD4 moiety of CD4-gp120 complex and prevents a post-binding event necessary for membrane fusion and viral infection.

The protein CD4 on the surface of Th cells and macrophages was identified as the receptor for HIV (1, 2), and its capacity to bind the viral envelope protein gp120 with high affinity was subsequently demonstrated (3). While this interaction is essential for the virus to eventually infect the target cells, there are indications that the CD4-gp120 binding initiates a chain of events, some of which may be equally important for virus penetration and infection. This is supported by claims that some antibodies directed against determinants positioned far from the CD4-binding site on gp120 (4) or against gp41 (5, 6) exhibit neutralizing capacity. This property is analogous to that of anti-envelope glycoprotein antibodies in the case of herpes and EBV (7, 8). We have observed a dissociation of neutralizing capacity and gp120 binding inhibition in anti-CD4 antibodies; this indicates a symmetrical relationship suggesting that events and/or signals occurring at the level of CD4 may represent such post-binding steps on the side of the cell membrane. For example, after binding to gp120, changes in conformation could reshuffle the fine antigenic structure, and new or modified epitopes associated with distinct functional states of the molecule may come into existence. Antibody binding to such induced or unmasked determinants could result in interruption of the chain of events leading to viral penetration of the cell.

With the aim of defining post-binding markers, we have

immunized mice with complexes of recombinant gp120 and CD4, and have obtained high titers of syncytia-blocking antibodies mainly directed at the CD4 moiety. In this report, we describe specificity and function of polyclonal and monoclonal antibodies resulting from these experiments, notably of those mAbs that inhibit syncytia formation by a mechanism different from blocking gp120-CD4 binding.

### Materials and Methods

**Recombinant Molecules.** Soluble rCD4, CD4 immunoadhesin (containing V1 and V2 domains of CD4 spliced to CH2 and CH3 domains of human IgG) (9), and rgp120 were produced by Genentech Inc. (South San Francisco, CA).

**Animals.** BALB-c female mice 10–15 wk old (The Jackson Laboratory, Bar Harbor, ME) were used both for immunization and for production of mAbs.

**Immunizations.** Mice were injected intraperitoneally with antigen emulsified in CFA (Difco Laboratories Inc., Detroit, MI). The antigens and doses were CD4, 12.8  $\mu$ g/mouse; gp120, 10  $\mu$ g/mouse; and CD4-gp120, 12.8  $\mu$ g CD4 and 10  $\mu$ g gp120, thoroughly mixed and incubated for 20 min, and then emulsified in CFA. The mice were bled before immunization and every week after, for 13 wk. Serum samples were stored at  $-20^{\circ}\text{C}$ .

**Enzymes and Substrates.** Alkaline phosphatase and glutaraldehyde, used to label antibodies for ELISAs, and substrate paranitro-

phenylphosphate (PNPP)<sup>1</sup> were acquired from Sigma Chemical Co. (St. Louis, MO).

**mAbs.** Our own mAbs mentioned in this paper are F-91-36, F-91-55, and F-91-94, hereafter called 36, 55, and 94, respectively. They are derived from a fusion of mouse 91, immunized with CD4-gp120 complex. All these are IgG1 subclass.

**Antibody Binding of gp120 and CD4.** ELISAs were performed by coating plates with 10 µg/ml gp120 or, respectively, with 3 µg/ml rCD4 and incubating them with serial dilutions of the mouse sera starting at 1:100. Phosphatase-labeled goat anti-mouse (GAM) IgG (Sigma Chemical Co.) was used to reveal bound antibodies. Readings were performed in a Titertek automated photometer (Flow Laboratories, Inc., McLean, VA).

**Inhibition of gp120 Binding to Solid-Phase CD4.** After coating the plates with 3–10 µg/ml rCD4, 50 µl of gp120 (5 µg/ml) was added and incubated for 1 h, plus or minus serial twofold dilution of test antiserum or antibody starting at 100 µg/ml concentration. After washing, phosphatase-labeled monoclonal anti-gp120 was applied and incubated for 1 h. The phosphatase activity was then measured by the rate of PNPP hydrolysis. The inhibition caused by the test antibody was expressed in percent decrease from the control gp120 binding.

**Effect of mAbs on CD4 Binding to Solid-Phase gp120.** Plates were coated with 3 µg/ml gp120. CD4-phosphatase at 10 and 3 µg/ml was incubated separately for 1 h with PTB (PBS [0.16 M, pH 7.2] containing 0.01% Tween 20 and 0.1% BSA) or with the test mAbs at concentrations of 0.3, 1, 3, and 10 µg/ml. Then, the mixtures were added to the coated wells and incubated for 1 h. After washing, the amount of bound CD4 was revealed by PNPP.

**Effect of gp120 on CD4 Binding to Solid-Phase Captured mAbs.** In separate 96-well plates, rgp120 and phosphatase-labeled rCD4 were serially titrated by 10-fold dilution from 80 and 40 µg/ml, respectively, in different directions on each plate. Equal volumes of each were then combined and incubated 2 h at room temperature (RT). Simultaneously with the above incubation, the test monoclonals were added to a GAM IgG-coated plate for 2 h at RT, then washed of excess sample. 50 µl of the titrated complex was transferred to the captured mAb-GAM plate and incubated at RT for 2 h, and then washed. PNPP substrate was added and the color was developed.

**Effect of gp120 on mAbs Binding to Solid-Phase CD4.** Plates were coated with 3 µg/ml rCD4. 25 µl of 0.1–1.0 µg/ml rgp120 and 25 µl of scalar concentrations (0.3–10.0 µg/ml) of test mAb were added together to the wells and incubated for 2 h. After washing, the bound mAb was revealed using GAM Ig phosphatase-labeled antibody.

**Crossinhibition of CD4 Binding.** Competition mapping of mAb specificities was performed by coating plates with rCD4 and layering alkaline phosphatase-labeled mAbs in the absence and presence of graded concentrations of unlabeled test mAbs whose specific binding sites are known from the literature. OKT4A (binding in V1) and OKT4 (binding in V4) were bought from Ortho Diagnostic Systems Inc. (Westwood, MA); anti-Leu-3a (binding in V1), L83 (VI-V2), L88 (V1), and L120 (V4) were gifts from Dr. David Buck, Becton Dickinson & Co. (Mountain View, CA).

**Inhibition of Syncytia Formation.** The cell fusion among CD4<sup>+</sup> cell lines acutely infected by the virus requires gp120-CD4-specific binding. The test was performed according to Matthews et al. (10). Briefly, CEM cells chronically infected with either HTLV3-III<sub>B</sub> or HTLV3-RF were used for each determination. Sera diluted 1:10

were distributed in 96-well A/2 plates (Costar, Cambridge, MA). 5–10 × 10<sup>3</sup> HIV-infected cells were added. 7 × 10<sup>4</sup> uninfected Molt 4 cells were admixed, and the plates were incubated overnight at 37°C, after which the number of giant cells (more than five times the size of the parental cells) were counted at 40×. The mouse serum control varied from 60 to 85 giant cells per well.

## Results


**Polyclonal Responses to Injection of Soluble CD4 (sCD4)-rgp120 Complexes in Mice.** Three groups of four mice were injected once, either with rCD4 alone (Fig. 1, A, D, and G), with sCD4-rgp120 complex (Fig. 1, B, E, and H), or with rgp120 alone (Fig. 1, C, F, and I). The weekly bleedings were titrated over a 3-mo period for capacity to bind CD4 (Fig. 1, D–F) and gp120 (Fig. 1, A–C), and for capacity to inhibit the formation of syncytia (Fig. 1, G–I). The overall results were strikingly different among the three groups. Fig. 1 displays the individual titers for each parameter and for each group. There were often multiple peaks during the response (D), and mice of a single group showed different timings for their peaks (D and H). When the timing and magnitude of the binding and neutralizing responses were examined: (a) there was no clear correlation between the titers of gp120 binding and syncytia blocking (B vs. H); (b) there was an inverse relationship between sCD4- and sCD4-rgp120-immunized groups when sCD4 binding titers and syncytia blocking were compared (D vs. G and E vs. H); or (c) there was a small CD4-binding response in the group immunized with rgp120, which could be attributed to antiidiotypes (F).

**Polyclonal Syncytia-blocking Responses by Mice Receiving CD4-gp120 Complexes Are not Type Specific.** The antisera from mice injected with CD4-gp120 efficiently block syncytia formation caused by such widely different HIV isolates as HTLV3-III<sub>B</sub> and HTLV3-RF. Fig. 2 shows individual titrations of the sera from these mice, revealing a similar rank order of the individual responses against the two isolates (93 > 94 > 91 > 92).


**The Syncytia-blocking Capacity of CD4-gp120 Responders Is Absorbed by CD4 and not by gp120.** To determine whether the high capacity of sera from complex-immunized mice to inhibit syncytia formation was due to anti-CD4 or anti-gp120 antibodies (or to a cooperative action of the two), a series of absorption experiments was performed using soluble and solid-phase bound antigens. The samples were subsequently monitored for changes in binding or syncytia-blocking titers. The results unequivocally attributed the syncytia-blocking capacity to antibodies that recognize the CD4 moiety of the complex rather than anti-gp120, since absorbed anti-gp120 serum shows unaltered syncytia blocking, while the decrease of CD4 binding is accompanied by a significant decrease of syncytia blocking with both isolates tested (Table 1).

**The Capacity to Inhibit CD4-gp120 Binding In Vitro Correlates with the CD4-binding Titer and not with the Syncytia-blocking Titer.** Since the syncytia-blocking capacity observed is mediated by anti-CD4, the inverse relationship of binding and syncytia-blocking titers in mice receiving CD4 vs. CD4-gp120 had to be attributed to a difference in the fine specificity of

<sup>1</sup> Abbreviations used in this paper: PNPP, paranitrophenylphosphate; RT, room temperature; sCD4, soluble CD4.



**Figure 1.** The time course of an experiment with three groups of mice injected with CD4 (A, D, and G), CD4-gp120 complex (B, E, and H), and gp120 (G, H, and I). The weekly serum samples were assayed individually for gp120-binding antibodies (A, B, and C), CD4-binding antibodies (D, E, and F), and syncytia-blocking capacity (G, H, and I). The mice immunized with the complex showed a somewhat higher anti-gp120 response than those immunized with gp120 alone (B vs. C); a markedly lower titer of CD4 binding as compared with those receiving CD4 alone (E vs. D); and a significantly higher syncytia-blocking response (H vs. G).



**Figure 2.** Titration of 11-wk serum from four mice injected with CD4-gp120 complex for III<sub>B</sub> and RF syncytia-blocking capacity. The parallel behavior of individual sera in the two tests suggests that the antibodies are directed at group-specific determinants.

the anti-CD4 antibodies in the two groups. To further characterize the anti-CD4 antibodies, one obvious test was to compare their relative capacity to inhibit gp120 binding to CD4. The results (Table 2) showed high inhibition titers in all mice immunized with CD4 alone and low titers in those immunized with the CD4-gp120 complex, indicating that the blocking of syncytia by the latter appears to be mediated by a mechanism other than prevention of binding of HIV to its receptor on the cell surface.

*Study of Anti-CD4-gp120 Responses Using mAbs.* To dissect the polyclonal response of mice immunized with CD4-

gp120 complex, hybridomas were produced from one of these animals, and the resulting antibodies were characterized for capacity to bind CD4, to bind gp120, and to block syncytia formation. Table 3 shows an early test of 170 wells with hybridoma clones, ordered according to their CD4 binding capacity. 30 (the majority) of the positive clones produced anti-CD4; only four produced anti-gp120, and the remainder were negative for both. Three of the anti-CD4 clones (and none of the anti-gp120) exhibited capacity to block syncytia. All borderline positives (i.e., those showing <0.100 in the gp120 binding) and those with partial blocking of syncytia (clones

**Table 1.** Absorption of Pooled Sera from Mice Immunized with CD4-gp120, Demonstrating that Syncytia Blocking Is Associated with anti-CD4

Absorbant	CD4 binding		gp120 binding		No. of syncytia <sup>†</sup>	
	OD*	%	OD*	%	IIIb	RF
None	1.216	(100)	0.940	(100)	0	3
gp120	1.180	(97)	0.188	(20)	0	5
CD4	0.420	(34)	0.936	(99)	11	24
No antiserum	-	-	-	-	52	60

\* OD<sub>405/60 min</sub> (color developed by phosphatase hydrolysis of PNPP).

† Syncytia blocking assay as described in Materials and Methods.

116, 95, and 32) became negative after subcloning. Table 4 shows a further characterization of the hybridomas when the inhibition of gp120-CD4 binding test was performed. The anti-CD4 mAbs can be divided into three categories: (a) those that do not inhibit gp120 binding and do not block syncytia; (b) those that do not inhibit gp120 binding and block syncytia; and (c) those that inhibit gp120 binding and block syncytia. mAbs 55 and 94 were further studied as representatives of the latter two categories, respectively. Both were of IgG1 isotype.

**Preliminary Mapping Experiments.** The binding site of both mAbs 55 and 94 was localized within the first two domains (V1-V2) of CD4 by binding experiments using the CD4 IgG immunoadhesin (Genentech), which contains the two external domains of CD4 spliced to an Ig C region (data not shown). A crossinhibition experiment using labeled mAbs 94 and 55 was performed. The binding of these mAbs to solid-phase CD4 was tested in the presence of a series of anti-CD4 mAbs whose epitopes and binding characteristics are known or partially known from the literature. The two mAbs were not inhibited by any of the tested antibodies with the exception of L83, which showed a partial competition with mAb 55 (Table 5). These results do not provide a precise mapping of the binding sites of the two mAbs. OKT4A and anti-Leu-3a bind in the first domain of CD4, and the test shows that neither binding site overlaps with mAbs 55 and 94. L83, according to unpublished data (David Buck, personal communication), recognizes a conformational determinant that is affected by mutations both in region 8-40 (V1) and region 119-188 (V2). These data, taken together, indicate that the fine specificity of mAbs 55 and 94 are different from most studied antibodies and different from each other.

**Interference of gp120 with CD4 Binding by mAbs.** Preliminary experiments had shown that mAb 94 blocked gp120 binding to CD4, while mAb 55 did not. To be able to detect both inhibition and possible cooperativity between antibody and gp120, we set up a series of three ELISAs by which the

**Table 2.** Difference in Fine Specificity Distribution among Polyclonal Anti-CD4 Antibodies

Pool	CD4 binding	Blocking gp120 binding	Fusion blocking
	$\mu\text{g/ml}$	$U_{50}/\text{ml}^*$	$U_{50}/\text{ml}^*$
9 (immunized CD4-gp120)	2.4	80.0	45.0
18 (immunized CD4)	31.0	890.0	7.0

\* One blocking  $U_{50}$  is the amount of antibody that reduces to 50% the amount of gp120 bound to CD4-coated wells or, respectively, the number of syncytia in the fusion test.  $U_{50}/\text{ml}$  was calculated by multiplying 1  $U_{50}$  by the dilution factor for each test.

ternary interaction of CD4, antibody, and gp120 was examined by keeping in turn one of the reactants in solid phase, and varying the concentrations of the other two. The results are shown in Figs. 3, 4, and 5, which also include curves obtained with reference antibodies OKT4A (which competitively interferes with CD4-gp120 binding) and OKT4 (which does not). In Fig. 3, the binding of labeled CD4 to gp120 is slightly enhanced or nonsignificantly changed in the presence of increasing concentrations of 55, while it is progressively inhibited by 94. In Fig. 4, the binding of labeled CD4 to solid-phase captured antibody is increased 40% by gp120 in the case of 55 at the highest concentration of CD4, but is unaffected or slightly decreased at lower concentrations of CD4. In the case of 94, there is progressive decrease of CD4 binding in the presence of increased gp120 concentrations, more evident when CD4 is limiting. In Fig. 5, the binding of labeled 55 to solid-phase CD4 is moderately enhanced in the presence of 0.1 or 1.0  $\mu\text{g/ml}$  gp120, while the binding of 94 is depressed in these conditions.

The conclusions of this series of experiments are that: (a) mAb 94 behaves always as an inhibitor/competitor of the CD4-gp120 binding; and (b) mAb 55 in certain conditions does not interfere with the binding in a way similar to OKT4, while in other conditions, it shows a degree of cooperativity with CD4-gp120 binding.

## Discussion

It is known that the HIV infection of CD4<sup>+</sup> cells can be prevented by antibodies specific for the gp120-binding site on CD4, defined as the V1 domain of CD4 involved in the initial CD4-gp120-binding event, i.e., the region homologous to CDR-2, amino acids 41-52 (11-14), and in part CDR-3, amino acids 83-92 (15, 16). These antibodies prevent infection by sterically interfering with the binding site.

We have obtained polyclonal and monoclonal antibodies from mice immunized with CD4 complexed to gp120 and, in this paper, we have described their binding characteristics

**Table 3.** List of Hybridomas Obtained from Fusion 91, Hierarchically Ordered According to their Supernatant's Capacity to Bind CD4, and Tested for Binding gp120 and Blocking Syncytia Formation

Hybridoma	Clone designation	Binding CD4	Binding gp120	No. of Syncytia at 1/2 dilution†	Syncytia blocking
1	135	1.363*	0*		
	144	1.208	0		
	148	1.149	0.007		
	75	1.059	0		
	215	1.049	0		
	145	0.982	0		
	84	0.932	0		
	142	0.930	0.012		
	140	0.837	0		
	10	210	0.724	0.015	
185		0.672	0		
143		0.599	0.009		
201		0.482	0		
J		0.437	0.006		
203		0.398	0.006		
15		0.385	0.010		
156		0.372	0.028		
58		0.313	0.011		
224		0.308	0		
20	146	0.255	0		
	55	0.182	0	9	80%
	165	0.157	0		
	36	0.153	0.041	0	100%
	172	0.145	0.006		
	94	0.136	0	0	100%
	223	0.125	0		
	59	0.121	0		
	V	0.109	0		
	R	0.106	0.012		
30	48	0.106	0		
	35	0	0.361		
	40	0	0.358		
	M	(0.023)	0.176		
	68	0	0.116		
	116	(0.012)	0	16	65%
40	95	0	0	18	60%
	32	0	0	18	60%
				(control 46)	
170	0	0			

\* OD<sub>405</sub>/120 min, when the supernatant was tested in ELISA on plates coated with CD4 (respectively, gp120) (see Materials and Methods).

† Only numbers lower than the control are shown.

and capacity to prevent the formation of HIV-dependent syncytia, while the study of their effect on cell-free virus infection is in progress. The data presented here, and also results in other laboratories (Q. Sattentau, personal communication), demonstrate that there are epitopes on CD4, unrelated to the binding site of gp120, which antibodies can recognize, thus affecting post-virus-binding events that usually lead to infection. Molecular transitions can be relatively slow, and it is conceivable that several successive steps, subsequent to binding, may be susceptible to interruption. The finding that anti-CD4 mAbs with different fine specificity show similar behavior is consistent with this scenario.

Antibodies that recognize viral envelope proteins have been shown to sometimes inhibit viral infection at a post-binding step both in the case of HIV (4-6) and herpes viruses (7, 8). Several of these antibodies are directed at proteins that mediate fusion of the viral envelope with the cell membrane, which normally results in virus penetration into the cytoplasm (9). The antibodies apparently bind to the fusogenic protein at a site that prevents its catalysis of the fusion event.

In the present case of HIV infection, it is not clear what post-binding step is being blocked. The bound antibody could possibly prevent lateral migration of the CD4 receptor in the plasma membrane preventing endocytosis, or block fusion of the viral envelope with either the cell plasma membrane or an endocytic vesicle membrane.

An alternative possibility is that the antibody may stabilize an intermediate conformation of CD4 and prevent it from reaching a state conducive to membrane fusion. In general, antibodies can stabilize a conformation, and thus stabilize (or "freeze") the antigen in a state that provides the highest affinity/lowest free energy to the paratope-epitope interaction. This mechanism has been studied in the case of antibody-mediated enzyme activation and stabilization, particularly in the *Escherichia coli*  $\beta$ -galactosidase system. The enzyme's tetra-

**Table 4.** Classification of mAbs from Mice Immunized with CD4-gp120 Complex


mAbs	Binding gp120	Binding CD4	Inhibiting CD4-gp120 binding*	Group-specific syncytia blocking
48, 35, 40 68	+	-	-	-
135, 144, 148 75, 215, 145 210, 185, 143	-	+	-	-
94, 36	-	+	+	+
55	-	+	-	+

\* Cut-off for a positive response was 25% blocking at a  $\geq$  1:2 dilution.

**Table 5.** Crossinhibition of CD4 Binding by mAbs 55 and 94

	OKT4A	Leu-3A	L83	L88	L92	L120	OKT4	F91-55	F91-94	F91-36
mAb 55	-	-	±	-	-	-	-	+	-	+
mAb 94	-	-	-	-	-	-	-	-	+	-

\* Cut-off point for positivity was 25% or larger decrease in binding when the inhibitor was six times more concentrated than the test mAb.




**Figure 3.** Effect of antibodies on rCD4-phosphatase binding to solid-phase rgp120. (A) OKT4A antibody; (B) 94 antibody; (C) OKT4 antibody; (D) 55 antibody. CD4-phosphatase concentrations: (●) 10 µg/ml; (○) 3 µg/ml. (y-axis) OD<sub>405</sub>/60 min; (x-axis) antibody concentration, from left to right, 0, 0.3, 1, 3, and 10 µg/ml.

meric conformation is stabilized in an enzymatically active state against denaturing conditions by polyclonal antibodies (Fabs) raised against the native enzyme (17, 18). Antibodies directed to a different epitope but present in the same antiserum tend to restore the native conformation in mutants defective in their dimer-dimer cohesion (19, 20). On the other hand, antibodies directed to the mutant configuration inhibit the antibody-mediated activation process by freezing the mutant conformation (21).


There are two distinct (but not mutually exclusive) mechanisms that could cause the differences observed between the polyclonal response of mice immunized with sCD4 vs. sCD4-rgp120 complex. One is the modification of the processing/presentation of the CD4 antigen because of its uptake in the form of a tightly bound complex with gp120. By analogy with what is known in the case of antibody-antigen complexes (22, 23), the presence of the ligand can affect the enzymatic breakdown of the immunogen and consequently the presentation of various peptides on class II MHC molecules. Consequently, the population of T specificities activated would differ in the two cases, and so would the T help for the various antibody-forming cells that can recognize CD4 epitopes.

The second, more direct possibility is an effect or combination of effects of the ligand on the B epitopes of the rCD4 molecule. For instance, the lower binding titers in mice injected with sCD4-rgp120 could be attributed to a "blanketing" effect of the large gp120 molecule over the relatively small CD4, many of whose epitopes would be hidden and thus unable to interact with the B cell surface Igs. In addition, the qualitative differences could be attributed to the appearance (caused by the binding of rgp120) of new or modified conformational epitopes that are absent or less represented in free molecules.

One aspect of the present results that should be noted is that the polyclonal response showed greater relative efficiency of syncytia blocking than the mAbs. This means that the small mAb population does not faithfully represent the clones active in the animals. It also supports the prediction that more varieties of antibodies recognizing intermediate epitopes, and thus possessing a greater ability to discriminate critical steps in the infection process, will be obtained by enlarging the number of immunized mice and the number of mAbs produced from them.



**Figure 4.** Effect of rgp120 on rCD4-phosphatase binding to various antibodies captured on solid-phase GAM Ig. (A) OKT4A antibody; (B) 94 antibody; (C) OKT4 antibody; (D) 55 antibody. Concentration of rCD4-phosphatase: (●) 10 µg/ml; (○) 1 µg/ml; (■) 0.1 µg/ml. (y-axis) OD<sub>405</sub>/60 min (A and B) or OD<sub>405</sub>/120 min (C and D); (x-axis) concentration of gp120 (0, 0.4, 4, and 40 µg/ml).



**Figure 5.** Effect of rgp120 on phosphatase-labeled antibody binding to solid-phase rCD4. (A) 94 antibody; (B) 55 antibody. (○) No rgp120; (●) rgp120 at 0.1 µg/ml; (■) rgp120 at 1.0 µg/ml. (y-axis) OD<sub>405</sub>/60 min; (x-axis) antibody concentrations (0.1, 1, 3, and 10 µg/ml).

We thank Dr. Dani Bolognesi for reading the manuscript and for many discussions, Dr. David Buck for the gift of a collection of mAbs with known anti-CD4 specificity, and Ms. Ann Rupel for expert preparation of the manuscript and figures.

This work was supported in part by U.S. Public Health Service Grants R01-AI-28194 (F. Celada) and 5P01-CA-43447 (T. Matthews), the Council for Tobacco Research grant 2298 to F. Celada, and American Foundation for AIDS Research Grant 000964-7-R9 (in memory of Ralph J. Eppensteiner) (F. Celada).

Address correspondence to Franco Celada, Room 1611, Hospital for Joint Diseases, 301 East 17th Street, New York, NY 10003. C. Cambiaggi's present address is the Department of Immunology, University of Verona, Verona, Italy.

Received for publication 9 May 1990 and in revised form 2 August 1990.

## References

1. Dalgleish, A.G., P.C.L. Beverley, P.R. Clapham, D.H. Crawford, M.P. Greaves, and R.A. Weiss. 1984. The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus. *Nature (Lond.)* 312:763.
2. Klatzman, D., E. Champagne, S. Chamaret, J. Gruest, D. Guetard, T. Hercend, J.C. Gluckman, and L. Montagnier. 1984. T lymphocyte T4 molecule behaves as the receptor for the human retrovirus, LAV. *Nature (Lond.)* 312:767.
3. Lasky, L.A. G. Nakamura, D.H. Smith, C. Fermie, C. Shimajaki, E. Patzer, P. Berman, T. Gregory, and D.J. Capon. 1987. Delineation of a region of the Human Immunodeficiency Virus Type I gp120 glycoprotein critical for interaction with the CD4 receptor. *Cell* 50:975.
4. Skinner, M.A., A.J. Langlois, C.B. McDanal, J.S. McDougal, D.P. Bolognesi, and T.J. Matthews. 1988. Neutralizing antibodies to an immunodominant envelope sequence do not prevent gp120 binding to CD4. *J. Virol.* 62:4195.
5. Dalgleish, A.G., T.C. Chanh, R.C. Kennedy, P. Kanda, P.R. Clapham, and R.A. Weiss. 1988. Neutralization of diverse HIV-1 strains by monoclonal antibodies raised against a gp41 synthetic peptide. *Virology* 165:209.
6. Evans, D.J., J. McKeating, J.M. Meredith, K.L. Burke, K. Katrak, A. John, M. Ferguson, P.D. Minor, R.A. Weiss, and J.W. Almond. 1989. An engineered poliovirus chimaera elicits broadly reactive HIV-1 neutralizing antibodies. *Nature (Lond.)* 339:385.
7. Fuller, A.O., and P.G. Spear. 1985. Specificities of monoclonal and polyclonal antibodies that inhibit adsorption of herpes simplex virus to cells and lack of inhibition by potent neutralizing antibodies. *J. Virol.* 55:475.
8. Miller, N., and L.M. Hutt-Fletcher. 1988. A monoclonal antibody to glycoprotein gp85 inhibits fusion but not attachment of Epstein-Barr Virus. *J. Virol.* 62:2366.
9. Byrn, R.A., J. Mordenti, C. Lucas, D. Smith, S.A. Marsters, J.S. Johnson, P. Cossum, S.M. Chamow, F.M. Wurm, T. Gregory, J.E. Groopman, and D.J. Capon. 1990. Biological properties of a CD4 immunoadhesin. *Nature (Lond.)* 344:667.
10. Matthews, T.J., K.J. Winhold, H.K. Lysterly, A.J. Langlois, H. Wigzell, and D.P. Bolognesi. 1987. Interaction between the human T-cell lymphotropic virus III<sub>B</sub> envelope glycoprotein gp120 and the surface antigen CD4: Role of carbohydrate in binding and cell fusion. *Proc. Natl. Acad. Sci. USA* 84:5424.
11. Peterson, A., and B. Seed. 1988. Genetic analysis of monoclonal antibody and HIV binding sites on the human lymphocyte antigen CD4. *Cell* 54:65.
12. Landau, N.R., M. Warton, and D.R. Littman. 1988. The envelope glycoprotein on the human immunodeficiency virus binds to the immunoglobulin-like domain of CD4. *Nature (Lond.)* 334:159.
13. Clayton, L.K., R.E. Hussey, R. Steinbrich, H. Ramachandran, Y. Hussain, and E.L. Reinherz. 1988. Substitution of murine for human CD4 residues identifies amino acids critical for HIV-gp120 binding. *Nature (Lond.)* 335:363.
14. Jameson, B.A., P.E. Rao, L.I. Kong, B.H. Hahn, G.M. Shaw, L.E. Hood, and S.B.H. Kent. 1988. Location and chemical synthesis of a binding site for HIV-1 on the CD4 protein. *Science (Wash. DC)* 240:1335.
15. Nara, P.L., K.M. Hwang, D.M. Rausch, J.D. Lifson, and L.E. Eiden. 1989. CD4 antigen-based antireceptor peptides inhibit infectivity of human immunodeficiency virus *in vitro* at multiple stages of the viral life cycle. *Proc. Natl. Acad. Sci. USA* 86:7139.
16. Sattentau, Q.J., J. Arthos, K. Deen, H. Hanna, D. Healey, P.C.L. Beverley, R. Sweet, and Alemseged Truneh. 1989. Structural analysis of the human immunodeficiency virus-binding domain of CD4. *J. Exp. Med.* 170:1319.
17. Melchers, F., and W. Messer. 1970. Enhanced stability against heat denaturation of *E. coli* wild type and mutant beta-galactosidase in the presence of specific antibodies. *Biochem. Biophys. Res. Commun.* 40:570.
18. Celada, F., R. Strom, and K. Bodlund. 1970. Antibody-mediated activation of a defective  $\beta$ -D-galactosidase (AMEF). Characteristics of binding and activation processes. In *The Lactose Operon*. J.R. Beckwith and D. Zipser, editors. Cold Spring Harbor Laboratories Press, Cold Spring Harbor, NY. 291-298.
19. Rotman, B., and F. Celada. 1968. Formation of  $\beta$ -D-galactosidase mediated by specific antibody in a soluble extract of *E. coli* containing a defective  $\alpha$  gene product. *Proc. Natl. Acad. Sci. USA* 60:660.
20. Celada, F., and R. Strom. 1972. Antibody-induced conformational changes in proteins. *Q. Rev. Biophys.* 5:395.
21. Celada, F., G. Ellis, K. Bodlund, and B. Rotman. 1971. Antibody-mediated activation of a defective  $\beta$ -D-galactosidase. II. Immunological relationship between the normal and the defective enzyme. *J. Exp. Med.* 134:751.
22. Manca, F., D. Fenoglio, A. Kunkl, C. Cambiaggi, M. Sasso, and F. Celada. 1988. Differential activation of T cell clones stimulated by macrophages exposed to antigen complexed with monoclonal antibodies. *J. Immunol.* 140:2893.
23. Manca, F., A. Kunkl, D. Fenoglio, A. Fowler, E. Sercarz, and F. Celada. 1985. Constraints in T-B cooperation related to epitope topology on *E. coli*  $\beta$ -galactosidase. I. The fine specificity of T cells dictates the fine specificity of antibodies directed to conformation-dependent determinants. *Eur. J. Immunol.* 15:345.